Navigation Links
S*BIO Completes US$26 Million Equity Financing
Date:10/20/2008

SINGAPORE, Oct. 20 /PRNewswire/ -- S*BIO Pte Ltd, a cancer therapeutics company, today announced the completion of a US$26 million Series B financing led by Bio*One Capital and new investor Aravis Venture. Additional new investors included the Lacuna Apo BioTech Fund advised by Adamant Biomedical Investments AG and Zurcher Kantonalbank (ZKB). S*BIO will utilize the proceeds to primarily fund the development efforts of its two lead compounds, SB939, a HDAC inhibitor, and SB1518, a JAK 2 inhibitor, both in Phase 1 clinical trials.

"We have been successful in attracting some of the top biotech investors in this round and we highly appreciate their enthusiasm, continued support and strong belief in our pipeline," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "As part of the financing, we would like to welcome Jean-Philippe Tripet, Managing Partner of Aravis to our Board of Directors. Mr. Tripet, with his extensive knowledge and experience in the life sciences arena, is a valuable addition to the Board."

"This financing round is a recognition of the progress we have made in rapidly and effectively developing our compounds. We look forward to having our lead compounds tested in Singapore, U.S. and other international trial sites and advancing them further into Phase 2 development"

Ms. Swee Yeok Chu, CEO of Bio*One Capital said "S*BIO has made excellent progress in developing a proprietary pipeline of drug candidates with exciting profiles. The financing will allow the company to accelerate the clinical development of its promising anti-cancer agents."

About SB939

SB939 belongs to a new class of targeted anti-cancer therapeutics called histone deacetylase (HDAC) inhibitors. SB939 is designed to be a "best-in-class" therapeutic amongst HDAC inhibitors being developed worldwide, and has demonstrated the potential to bring additional therapeutic benefits due to its high potency, superior oral availability and good tolerability. SB939 is
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4

Related biology technology :

1. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
2. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
3. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Carrington Completes $8 Million Financing
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. New Brunswick Scientific Completes Merger Transaction with Eppendorf
8. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
9. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Companys Partner Completes Trial Production of a New Antiviral Medicine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...eneration of ultrasmall transistors and more power...miconducting nanowires are closer to reality after...versity and the University of California at Los An...ate nanowires with layers of different materials t... is a critical requirement for making efficient tr...
(Date:11/25/2009)... to Speak at Economic Club of Canada , ... 2009 -- Ambassador to Speak at Economic Club of C...or for International Investment, and Chairman and ...raphy of David Appia go to www.investinfrance.org...eet with press to discuss recent pro-business init...
(Date:11/25/2009)... 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SV...announced today that it executed,a joint venture (...e,Technology Co., Ltd. (Sinovac Dalian). The JV wi...man-use vaccines. Sinovac will contribute its expe...zing world-class vaccines; the,other party will br...
(Date:11/24/2009)...man . , Whether it,s CD packaging, container...ncy Identification) are increasingly finding their...label objects or goods and identify them automatic...an read and process the data contained in the labe...uction conditions of up to 100 degrees Celsius. Bu...
Breaking Biology Technology:Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3French Ambassador for International Investment to Visit Toronto December 11 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Intelligence inside metal components 2
...mentally Responsible Site to Significantly Increas...China, CAMBRIDGE, Mass., April 22 Genzyme Corp.,...d a major new research and,development center in B...Genzyme,s ongoing global expansion and commitment ...he new facility will be used for research and deve...
...ON, N.J., April 22 Medarex, Inc.,(Nasdaq: MEDX )...t the,Morgan Stanley Global Healthcare Unplugged C..., 2008. The event will be webcast live and will be...e Medarex website at, http://www.medarex.com . An ...able,following the event., About Medarex, Medare...
...n-HDL and apoB measurement helps physicians guide ...sk patients, BIRMINGHAM, Ala., April 22 The dete...ed as valid, accurate and recommended,methods of g...patients with,cardiometabolic risk (CMR). The VAP(... commercially available advanced lipid profile tha...
Other Biology Technology:Genzyme to Build New R&D Center in Beijing 2Genzyme to Build New R&D Center in Beijing 3Genzyme to Build New R&D Center in Beijing 4Genzyme to Build New R&D Center in Beijing 5Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients 2Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients 3
(Date:11/24/2009)... Spanish . , The presence of increased body...substances in the blood, hinders the loss and main...ject of the University of Navarra conducted by Est...f Pharmacy. , The project, entitled "A nutrigene...rol of body weight and inflammation," examines how...
(Date:11/23/2009)...- The time of day matters to forest trees dealing ... a research team led by Professor Malcolm Campbell...al for research and colleagues in the department o...s. , Capitalizing on their previous work to de...eam examined how poplar trees use their 45,000 gen...
(Date:11/23/2009)...y provides "incontrovertible evidence" that the vo...atra about 73,000 years ago deforested much of cen...esearchers report. , The volcano ejected an esti...ere, leaving a crater (now the world,s largest vol...ometers wide. Ash from the event has been found in...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2Time of day matters to thirsty trees, U of T researcher discovers 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2China Medicine Enhances Management Team with Appointments of New Chief Financial Officer and Finance Manager 55690 1China Medicine Enhances Management Team with Appointments of New Chief Financial Officer and Finance Manager 55690 2China Medicine Enhances Management Team with Appointments of New Chief Financial Officer and Finance Manager 55690 3China Medicine Enhances Management Team with Appointments of New Chief Financial Officer and Finance Manager 55690 4Prostate Net Announces 3A Inaugural Fore 21 Informed Decisions Golf Outing 55688 1Prostate Net Announces 3A Inaugural Fore 21 Informed Decisions Golf Outing 55688 2Prostate Net Announces 3A Inaugural Fore 21 Informed Decisions Golf Outing 55688 3Prostate Net Announces 3A Inaugural Fore 21 Informed Decisions Golf Outing 55688 4Rib X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram negative Bac 13736 1Rib X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram negative Bac 13736 2Rib X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram negative Bac 13736 3
...y hold the key to many of the challenges we face t...tion, and yet scientists estimate that they have d...pecies. , Helping students delve into such unchar... their interest and motivation in science and rese...ter. The Center, to be launched later this month, ...
..., CA (March 20, 2009) A rigorous environmental cle...methicillin-resistant Staphylococcus aureus (MRS...ital intensive care units (ICUs), according to a n...he Society for Healthcare Epidemiology of America ...ced cleaning protocol reduced the spread of MRSA t...
.... Scientists at Duke University Medical Center ha...ut some smokers at significantly higher risk of de...PD). , The findings come from the first-ever gen...t those who carry the markers may be able to reduc... symptoms of COPD occur. , "The public health mes...
Other Biology News:Bioscience institutions come together to launch Microlife Discovery Center for area students 2Bioscience institutions come together to launch Microlife Discovery Center for area students 3Environmental cleaning intervention reduces transmission of multidrug-resistant organisms in ICUs 2Genetic irregularities linked to higher risk of COPD among smokers 2
Rhesus Monkey IFN-Alpha from Cell Sciences
Bovine DNP-BSA (Bovine Serum Albumin), BSA (Bovine Serum Albumin) conjugated/tagged from Biosearch Technologies
Bovine NIP-BSA (Bovine Serum Albumin), BSA (Bovine Serum Albumin) conjugated/tagged from Biosearch Technologies
Amino Acid Analysis from Bio-Synthesis
Biology Products: